Nasdaq

Lipella Pharmaceuticals Reports Positive Phase 2a Results for LP-310 Oral Rinse in Treating Oral Lichen Planus

LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...
Seeking Alpha

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision ...

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced additional ...
Morningstar

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison ...

PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and ...
Nasdaq

Lipella Pharmaceuticals Inc. Reports Positive Topline Results from Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Inc. announced positive topline results from the second cohort of its Phase 2a clinical study of LP-310, a liposomal-tacrolimus oral rinse aimed at treating oral lichen planus ...